Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

Results from two separate Phase 1 studies show sobetirome, a selective

thyroid hormone receptor beta agonist, reduced levels of low-density

lipoprotein versus placebo

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.

"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.

Study Results

Lipid-lowering effects in both single and multiple doses were seen in the randomized, double-blind, placebo-controlled Phase 1 studies of sobetirome. In the single dose study of 32 subjects, low-density lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects receiving up to 450 micrograms of sobetirome, compared to 2% in subjects who received placebo. The greatest reductions were observed 72 hours after dosing. In
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... The ... funds, investment firms and animal health companies to hear from animal health companies ... Several have also received licensing agreements or distribution contracts. This meeting is ...
(Date:8/27/2015)... 2015  Neogen Corporation (NASDAQ: NEOG ) announced ... United Kingdom -based Lab M Holdings, a ... diagnostic systems. Lab M was founded ... of microbial testing and diagnostic products for the global ... currently sells into more than 70 countries worldwide, and ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... six-month periods ended June 30, 2015. Biorem,s complete second quarter financial ... FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , ... 2014 , 2015 , 2014 Revenue , ... , 4,433 Gross profit , 1,656 , ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
... 7 OncoMed Pharmaceuticals, Inc., a clinical-stage company developing ... announced the appointment of Sunil Patel to the position ... new position, Mr. Patel will have primary responsibility for ... OncoMed,s President and Chief Executive Officer. , , ...
... , SUMMERVILLE, S.C., July 7 ArborGen, LLC, ... announced wood quality results from ongoing field trials that ... AMEX: SNT ). The two companies ... have shown significantly enhanced growth rates in 3-year-old field ...
... FREMONT, Calif., July 7 /PRNewswire-FirstCall/ -- ... leading developer of state-of-the-art genetic analysis systems, today announced ... will be presented at GTCbio,s 3rd Annual Rediscovering Biomarkers ... Kastury, Ph.D., WaferGen,s vice president, research and technical operations, ...
Cached Biology Technology:OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development 2ArborGen and Senesco Announce Wood Quality Results 2ArborGen and Senesco Announce Wood Quality Results 3ArborGen and Senesco Announce Wood Quality Results 4Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 2Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 3Data on WaferGen's SmartChip(TM) System to be Presented at 3rd Annual Rediscovering Biomarkers Conference 4
(Date:8/20/2015)... Aug. 20, 2015   Sensory, Inc ., ... the user experience and security of consumer electronics ... announced that its TrulySecure™ is the ... to be FIDO Certified™. The FIDO ... with the FIDO UAF (Universal Authentication Framework) 1.0 ...
(Date:8/17/2015)... 17, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market and creator of ... for Q4 2015. The new marketing campaign is being ... Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( ... leader in retail driven marketing and brand awareness and ...
(Date:8/11/2015)... GOTHENBURG, Sweden , August 11, 2015 ... sensor FPC1155. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a prominent smartphone manufacturer ... ZUK selected FPC1 155 ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2
... study involving the world,s deadliest substance has yielded a new ... more efficient strategies against toxins that may be used in ... and even some important chronic diseases. A Tufts-led ... that seek out Botulinum toxin molecules and bind to them ...
... over hundreds of generations to infect bacteria. They found ... at a quicker rate and generated greater diversity, compared to ... viral infection. The study shows, for the first time, ... in his ,Red Queen Hypothesis,. The theory, first put ...
... Iowa study supports an earlier UI report that found polychlorinated ... Canal (IHSC) in East Chicago, Ind. The study also presents ... PCBs found in surrounding air and in Lake Michigan. ... Environmental Science and Technology (ES&T), a publication of ...
Cached Biology News:Novel antitoxin strategy developed using 'tagged binding agents' 2Novel antitoxin strategy developed using 'tagged binding agents' 3Scientists reveal driving force behind evolution 2UI study measures levels of PCBs flowing from Indiana canal to air and water 2